The AI-based Progression and Medication Response Prediction (AI-PMP) study initiation is in progress. On 15 April 2025, the first study protocol was submitted for ethics approval by CHU de Toulouse in France. Submissions in Spain (Fundación INCE) and Germany (Technische Universität Dresden) are currently in progress.

The AI-PMP study is a multi-centre, proof-of-concept study. It aims to:

• Validate AI models that predict Parkinson’s disease (PD) progression and medication response

• Provide preliminary evidence of clinical utility

• Evaluate the usability of the mAI-Care and mAI-Insights apps by people with PD and healthcare professionals.

The PD progression model uses a combination of clinical, phenotypic, genetic, and digital biomarker data gathered from daily life to forecast disease evolution. The study will contribute to the clinical validation of AI models aimed at supporting Parkinson’s care.

Read more about AI-PROGNOSIS clinical studies: https://www.ai-prognosis.eu/clinical-studies